Endocrine Abstracts (2011) 26 P494

Effects of ibandronate versus risedronate on hip bone density in the osteoporotic elderly

Ilkin Naharci1, Ahmet Turan Isik1, Ergun Bozoglu1, Ozdes Emer2, Turker Turker3, Metin Uyanik4, Muhittin Serdar4 & Huseyin Doruk1


1Division of Geriatrics, Gulhane Medical Faculty Training Hospital, Department of Internal Medicine, Ankara, Turkey; 2Gulhane Medical Faculty Training Hospital, Department of Nuclear Medicine, Ankara, Turkey; 3Gulhane Medical Faculty Training Hospital, Department of Epidemiology, Ankara, Turkey; 4Gulhane Medical Faculty Training Hospital, Department of Medical Biochemistry, Ankara, Turkey.


Introduction: The aim of this study was to investigate whether monthly ibandronate improves hip bone mineral density (BMD) to the same degree as weekly risedronate in osteoporotic elderly.

Material and methods: Eighty-one older adults with osteoporosis, age ranging from 65 to 95 years (mean: 77.5 years) were completed the study. Patients were treated either ibandronate 150 mg once monthly (n=56) and risedronate 35 mg once weekly (n=25). Changes in BMD at the total hip, neck, and trochanter, changes in bone turnover markers, and safety were compared at 12 months.

Results: There were no significant differences in all baseline parameters for two groups. After treatment in the ibandronate group, BMD was significantly increased by 3.86, 3.31, and 3.71% at the total hip, neck, and trochanter, respectively, as compared with baseline (P<0.001, for all comparisons). In the risedronate group, BMD was also significantly increased by 3.60, 3.24, and 3.78% at the total hip, neck, and trochanter, respectively, as compared with baseline (P<0.001 for total hip and trochanter; P=0.003 for neck). No differences in BMD changes at total hip, neck, and trochanter were found between two groups, respectively (P=0.323, P=0.523, P=0.985). The changes in bone turnover markers (urine hydroxyproline and serum total alkaline phosphatase) were −3.93 and −24.7% for ibandronate group and −5.58% and −22.4% for risedronate group, respectively. No significant difference in the incidence of adverse events was found between two treatment groups.

Conclusion: Our findings indicate that monthly ibandronate was as effective as weekly risedronate at increasing hip BMD after 12 months in elderly with OP. Use of monthly ibandronate possibly could improve compliance and persistence as compared weekly therapies and could be good option to minimize polypharmacy in elderly people.

Article tools

My recent searches

No recent searches.